|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Diabetic Macular Edema: What Is Focal and What Is Diffuse?显示文摘 | David J. Browning Michael M. Altaweel Neil M. Bressler Susan B. Bressler Ingrid U. Scott | 2008 | American Journal of Ophthalmology2008，，5： | 2 |
| 2 | 糖尿病患者哌加他尼治疗后视网膜新生血管的变化显示文摘Objective: To study effects of intravitreal pegaptanib (Macugen) on retinal neovascularization. Design: Retrospective analysis of a randomized clinical trial. Participants, Intervention, and Main Outcome Measures: Individuals with retinal neovascularization identified from a multicenter, randomized, controlled trial evaluating pegaptanib for treatment of diabetic macular edema, with a best-corrected visual acuity letter score between 68 and 25 (approximate Snellen equivalent between 20/50 and 20/320) and receiving a sham injection or intravitreal pegaptanib (0.3 mg, 1 mg, 3 mg) administered at study entry, week 6, and week 12, with additional injections and/or focal photocoagulation as needed during the ensuing 18 weeks, up to a maximum of 6 pegaptanib/sham therapies, were evaluated. Scatter panretinal photocoagulation before study enrollment was permitted, but not within 6 months of randomization and study entry. Changes in retinal neovascularization were assessed on fundus photographs and fluorescein angiograms graded at a reading center in a masked fashion. Results: Of 172 participants, 19 had retinal neovascularization in the study eye at baseline. Excluding 1 who had scatter photocoagulation 13 days before randomization and 2 with no follow-up photographs, 1 of the remaining 16 subjects had panretinal photocoagulation during study follow-up. Of these 16 subjects, 8 of 13 (62%) in a pegaptanib treatment group (including the one receiving panretinal photocoagulation), 0 of 3 in the sham group, and 0 of 4 fellow (nonstudy) eyes showed either regression of neovascularization on fundus photographs or regression or absence of fluorescein leakage from neovascularization (or both) at 36 weeks. In 3 of 8 with regression, neovascularization progressed at week 52 after cessation of pegaptanib at week 30. Conclusions: Most subjects with retinal neovascularization at baseline assigned to pegaptanib showed regression of neovascularization by week 36. These findings suggest a direct effect of pegaptanib upon retinal neovascularization in patients with diabetes mellitus. | Bressler N. M Altaweel M 王静波(译) | 2006 | 世界核心医学期刊文摘(眼科学分册)2006，2，5： | 1 |
| 3 | A phase Ⅱ randomized double-masked trial of pegaptanib,an anti-vascular endothelial growth factor aptamer,for diabetic macular edema显示文摘 | Cunningham ET Jr Adamis AP Altaweel M | 2005 | Ophthalmology2005，112，： | 1 |
| 4 | Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals 显示文摘 | Adamis AP Altaweel M Bressler NM Cunningham ET Jr Davis MD Goldbaum M | 2006 | Ophthalmology2006，113，1： | 1 |
| 5 | Diabetic macular edema:what is focal and what is diffuse? 显示文摘 | Browning D J Altaweel M M Bressler N M | 2008 | Am J Ophthalmol2008，146，5： | 1 |
| 6 | Arabic validation of the short form of urogenital distress inventory (UDI-6)questionnaire 显示文摘 | Altaweel W Seyam R Mokhtar A | 2009 | Neur- ourel Urodyn2009，28，4： | 1 |
| 7 | Macular hole:improved understanding of pathogenesis, staging, and management based on optical coherence tomography显示文摘 | M. Altaweel M. Ip | | 0，，02： | 1 |
| 8 | A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer , for diabetic macular edema 显示文摘 | Cunningham ET Jr Adamis AP Altaweel M Aiello LP Bressler NM D' Amico DJ | 2005 | Ophthalmology2005，112，10： | 1 |
| 9 | A phase ll randomized double-masked trial of pegaptanib,an anti-vascular endothelial growth factor aptamer, tbr diabetic macular edema显示文摘 | Cunningham El' Adamis AP Altaweel M | 2005 | Ophthalmology2005，112，10： | 1 |
| 10 | Intravitreal triamcinolone acetonide treatment for macular edema from central retinal vein occlusion 显示文摘 | Ip MS Gottlieb JL Kahana A Scott IU Altaweel MM Blodi BA | 2004 | Arch Ophthal- mo/2004，122，8： | 1 |
| 11 | 查看详情显示文摘 | Altaweel A M A M Ranganathaiah C Siddramaiah B | | 0，，： | 1 |
| 12 | Urinary incontinence:prevalence,risk factors,and impact on health related quality of life in Saudi women显示文摘 | Altaweel W Alharbi M | 2012 | Neurourol Urodyn2012，31，5： | 1 |
| 13 | A phase Ⅱrandomized double-masked trial of pegaptanib,an anti-vascular endothelial growth factor aptamer,for diabetic macular edema显示文摘 | Cunningham ET Jr Adamis AP Altaweel M | 2005 | Ophthalmology2005，112，： | 1 |
| 14 | Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals显示文摘 | Adamis A P Altaweel M Bressler N M | 2006 | Ophthalmology2006，113，1： | 1 |
| 15 | A phase Ⅱ randomized double-masked trial of pegaptanib,an anti-vascular endothelial growth factor aptamer,for diabetic macular edema显示文摘 | Cunningham ET Jr Adamis AP Altaweel M Aiello LP Bressler NM D'Amico DJ | 2005 | Ophthalmology2005，112，10： | 1 |
| 16 | Changes in retinal neovascularization after pegaptani ( Macugen ) therapy in diabetic individuals 显示文摘 | Adamis AP Altaweel M Bressler NM Cunningham ET Davis MD Goldbaum M | 2006 | Ophthalmology2006，113，1： | 1 |
| 17 | Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals显示文摘 | Adamis AP Altaweel M Bressler NM Cunningham ET Jr Davis MD Goldbaum M | 2006 | Ophthalmoloay2006，113，1： | 1 |
| 18 | A phase II randomized double-masked trial of pegaptanib, an anti-vascular en- dothelial growth factor aptamer, for diabetic macular edema显示文摘 | Cunningham El' Jr Adamis AP Altaweel M | 2005 | Ophthalmology2005，112，10： | 1 |
| 19 | A phase Ⅱ randomized double - masked trial of pegaptanib, an anti - vascular endothelial growth factor aptamer, for diabetic macular edema显示文摘 | CUNNINGHAM E TJ R ADAMIS A P ALTAWEEL M | 2005 | Ophthalmology2005，112，10： | 1 |
| 20 | A phase H randomizeddouble-masked trial of pegaptanib,an anti-vascular endothelial growthfactor aptamer,for diabetic macular edema 显示文摘 | Cunningham ET Jr Adamis AP Altaweel M | 2005 | Ophthalmology2005，112，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员